Login to Your Account

Tufts report: Biopharma heeding call to improve drug trial performance

By Marie Powers
News Editor

Wednesday, January 27, 2016

Responses from 30 participants in a recent roundtable as part of the Tufts Center for the Study of Drug Development (CSDD) Executive Forum indicated that 48 percent of their phase II and III trial sites missed enrollment targets in 2015 and 11 percent failed to recruit a single patient.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription